Medications

What Is Retatrutide? A New Triple-Hormone Weight Loss Medication

If you've been following the remarkable evolution of weight loss medications, you've likely heard about GLP-1 agonists like semaglutide and tirzepatide. But there's a new player generating significant excitement in the medical community: retatrutide. While not yet FDA-approved, this investigational medication is showing unprecedented results in clinical trials, and understanding what it is—and how it works—can help you make informed decisions about your weight loss journey.

What Is Retatrutide?

Retatrutide is an investigational weight loss medication currently in Phase 3 clinical trials. Unlike current GLP-1 medications, retatrutide is a triple-hormone receptor agonist, meaning it activates three different hormone pathways in your body simultaneously.

Specifically, retatrutide activates:

This triple-action approach represents a significant advancement from current medications like semaglutide (which targets only GLP-1) and tirzepatide (which targets GLP-1 and GIP). By adding glucagon receptor activation, retatrutide appears to enhance metabolic effects beyond what we've seen with existing treatments.

How Does Retatrutide Work?

Each of retatrutide's three mechanisms contributes to weight loss and metabolic health in distinct ways.

GLP-1 Activation

Like medications you may already know, the GLP-1 component helps reduce appetite, slow stomach emptying, and improve blood sugar control. This is the same mechanism that's made semaglutide and tirzepatide so effective for weight management.

GIP Activation

The GIP component works alongside GLP-1 to further enhance insulin secretion and may improve how your body stores fat. This dual approach is what makes tirzepatide effective, and retatrutide builds on this foundation.

Glucagon Activation

Here's where retatrutide gets interesting. The glucagon component increases energy expenditure and may help your body burn more calories at rest. It also appears to specifically target fat breakdown, which could explain the impressive weight loss results seen in clinical trials.

Clinical Trial Results: What the Research Shows

The results from retatrutide clinical trials have been striking. In a 48-week Phase 2 study published in the New England Journal of Medicine, participants taking the highest dose of retatrutide lost an average of 24% of their body weight.

To put this in perspective, that's significantly more than what we typically see with current medications. Semaglutide trials showed average weight loss of about 15%, while tirzepatide trials demonstrated roughly 21% weight loss at the highest doses.

Beyond weight loss, trial participants also experienced improvements in:

These metabolic benefits suggest retatrutide could offer comprehensive health improvements beyond the number on the scale.

Gender Differences in Response

While clinical trial data is still emerging, early evidence suggests both men and women respond well to retatrutide. Some studies indicate women may experience slightly different rates of certain side effects, particularly nausea, though this pattern is similar to what we see with current GLP-1 medications. Researchers continue to analyze how hormonal differences might influence treatment outcomes and optimal dosing strategies.

Side Effects and Safety Profile

Because retatrutide is still in clinical trials, we're continuously learning about its safety profile. The most commonly reported side effects mirror those of other GLP-1 medications:

Most side effects were mild to moderate and decreased over time as participants adjusted to the medication. However, it's important to note that long-term safety data is still being collected.

As with any medication, some people had to discontinue treatment due to side effects. The trial discontinuation rates were similar to those seen with tirzepatide and semaglutide.

When Will Retatrutide Be Available?

Retatrutide is currently not FDA-approved and remains in Phase 3 clinical trials. The manufacturer, Eli Lilly, is conducting multiple large-scale studies examining retatrutide for both obesity and related metabolic conditions.

If trials continue to show positive results and the medication receives FDA approval, retatrutide could potentially become available sometime in 2026 or 2027. However, timelines for drug approval can shift based on regulatory requirements and trial outcomes.

How Does Retatrutide Compare to Current GLP-1 Medications?

While we can't make definitive comparisons until retatrutide is fully studied and approved, here's what we know so far:

Effectiveness

Early data suggests retatrutide may produce greater weight loss than current options, likely due to its triple-hormone mechanism. However, individual responses to any medication vary considerably.

Dosing

Retatrutide in trials was administered as a once-weekly injection, similar to semaglutide and tirzepatide. This convenience factor remains consistent across these newer medications.

Cost

Pricing information won't be available until closer to potential FDA approval. However, newer medications typically launch at premium prices, which is why compounded versions of currently available medications like semaglutide and tirzepatide offer more accessible options today.

What This Means for Your Weight Loss Journey Today

While retatrutide's results are exciting, it's important to focus on proven treatments available now. Semaglutide and tirzepatide are already producing life-changing results for thousands of people, with established safety profiles and FDA approval.

The promising research on retatrutide does reinforce what we're learning: targeting multiple metabolic pathways can produce significant, sustained weight loss when combined with lifestyle changes. This validates the approach of current medications and gives us optimism for continued advancement in this field.

If you're considering weight loss medication, there's no need to wait. The medications available today are highly effective, well-studied, and can help you start making progress toward your health goals now.

From the Ozari Care Team

While retatrutide shows tremendous promise, we encourage our patients to focus on evidence-based treatments available today. Semaglutide and tirzepatide have helped thousands achieve meaningful, sustained weight loss with well-established safety profiles. The future of metabolic medicine is bright, but the tools to transform your health are already here.

Start Your Weight Loss Journey Today

At Ozari Health we offer compounded Semaglutide and Tirzepatide as low as $99/month prescribed by licensed physicians and shipped to your door. Learn more at ozarihealth.com.

Medically Reviewed — Ozari Clinical Content Team (OCCT). Health writers and wellness professionals specializing in GLP-1 therapy, metabolic health, and weight loss medicine. Content reviewed in accordance with Ozari's Editorial Standards. Last reviewed: April 25, 2026.

This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting any medication.

Last reviewed: April 25, 2026